IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 196 filers reported holding IMPAX LABORATORIES INC in Q1 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,938,000 | +18.5% | 151,134 | +1.5% | 0.00% | 0.0% |
| Q4 2017 | $2,480,000 | -17.9% | 148,859 | +0.3% | 0.00% | 0.0% |
| Q3 2017 | $3,019,000 | +31.7% | 148,419 | +4.2% | 0.00% | 0.0% |
| Q2 2017 | $2,292,000 | +37.4% | 142,452 | +8.1% | 0.00% | +100.0% |
| Q1 2017 | $1,668,000 | -3.9% | 131,834 | +0.5% | 0.00% | -50.0% |
| Q4 2016 | $1,736,000 | +9.4% | 131,224 | +95.7% | 0.00% | 0.0% |
| Q3 2016 | $1,587,000 | +250.3% | 67,046 | +326.4% | 0.00% | – |
| Q2 2016 | $453,000 | -9.8% | 15,722 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $502,000 | -18.1% | 15,722 | +10.4% | 0.00% | 0.0% |
| Q4 2015 | $613,000 | +31.5% | 14,241 | +5.0% | 0.00% | 0.0% |
| Q3 2015 | $466,000 | -21.8% | 13,557 | +4.4% | 0.00% | 0.0% |
| Q2 2015 | $596,000 | +2.1% | 12,985 | +3.9% | 0.00% | 0.0% |
| Q1 2015 | $584,000 | +79.1% | 12,497 | +22.8% | 0.00% | – |
| Q4 2014 | $326,000 | +29.9% | 10,175 | -2.0% | 0.00% | – |
| Q3 2014 | $251,000 | – | 10,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 423,161 | $13,406,000 | 7.47% |
| Aravt Global | 2,300,000 | $72,864,000 | 5.43% |
| Slate Path Capital LP | 2,330,000 | $73,814,000 | 5.16% |
| Orbimed Advisors | 6,678,000 | $211,559,000 | 2.02% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Penn Capital Management Company, LLC | 709,045 | $22,463,000 | 0.94% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $7,920,000 | 0.79% |
| NEW AMSTERDAM PARTNERS LLC/NY | 276,169 | $8,749,000 | 0.76% |
| Matarin Capital Management, LLC | 52,932 | $1,676,886,000 | 0.74% |